A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma

Yi Wang; Weirong Qin; Hongdong Shi; Haijie Chen; Xiaoyan Chai; Jingang Liu; Pingyu Zhang; Zigang Li; Qianling Zhang

doi:10.1039/C9DT03856F

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma†

Yi Wang,‡^ab Weirong Qin,‡^cd Hongdong Shi,^b Haijie Chen,^b Xiaoyan Chai,^b Jingang Liu,

*^a Pingyu Zhang,

*^b Zigang Li

*^cd and Qianling Zhang

*^b

Author affiliations

* Corresponding authors

^a Key Laboratory for Advanced Materials of MOE, School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai, P. R. China
E-mail: liujingang@ecust.edu.cn

^b College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen Key Laboratory of Functional Polymer, Shenzhen, P. R. China
E-mail: p.zhang6@szu.edu.cn, zhql@szu.edu.cn

^c School of Chemical Biology and Biotechnology, Shenzhen Graduate School of Peking University, Shenzhen, China
E-mail: lizg@pkusz.edu.cn

^d Pingshan translational medicine center, Shenzhen Bay Laboratory, Shenzhen, P. R. China

Abstract

An HCBP1 peptide–ruthenium conjugate (Ru–β-Ala-FQHPSFI) as a potential candidate for targeted therapy of hepatoma was synthesized. Ru–β-Ala-FQHPSFI shows drastically enhanced cytotoxicity and high selectivity for hepatoma cells versus noncancer liver cells. Raman imaging shows that this peptide-based drug can be taken up well by the hepatoma cells compared with the bare ruthenium complex (Ru) and the opposite sequence peptide–ruthenium conjugate (Ru-β-Ala-IFSPHQF). This study presents a new strategy for the construction of tumor-targeting metal-based anticancer therapeutics.

Download options Please wait...

Supplementary files

Supplementary information PDF (983K)

Article information

DOI: https://doi.org/10.1039/C9DT03856F
Article type: Communication
Submitted: 30 Sep 2019
Accepted: 09 Dec 2019
First published: 10 Dec 2019

Download Citation

Dalton Trans., 2020,49, 972-976

Permissions

Request permissions

A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma

Y. Wang, W. Qin, H. Shi, H. Chen, X. Chai, J. Liu, P. Zhang, Z. Li and Q. Zhang, Dalton Trans., 2020, 49, 972 DOI: 10.1039/C9DT03856F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Social activity

Fetching data from CrossRef.
This may take some time to load.

Dalton Transactions

A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma†

Abstract

Supplementary files

Article information

Download Citation

Permissions

A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma

Social activity

Search articles by author

Spotlight

Advertisements